Otsuka has reported positive full results from its Phase 3 VISIONARY trial, showing its drug Voyxact stabilised kidney function in adults with IgA nephropathy over two years. Voyxact, known clinically as sibeprenlimab-szsi,
More
The pharmaceutical industry has reached a pivotal moment at the midpoint of 2026, shaped by an accelerating dealmaking environment and rapidly shifting patient access dynamics. A widening gap in patient affordability is
More
The Office of Management and Budget published the Trump Administration’s 2026 Unified Agenda in July, outlining regulatory priorities across multiple federal agencies. Among the most significant entries, the USDA’s portion of the
More
On 28 July 2026, the Federal Communications Commission’s Public Safety and Homeland Security Bureau released Public Notice DA 26-786, adding foreign-produced advanced robotic devices to the FCC’s Covered List. The Covered List
More
Fauci’s appearance before Congress drew sharp criticism from conservative commentators after he repeatedly declined to answer questions under oath. The former director of the National Institute of Allergy and Infectious Diseases invoked
More
Acting Attorney General Todd Blanche posted a signed order to X late Sunday night formally rescinding the controversial Anti-Weaponization Fund he personally created earlier this year. The fund was established as part
More
The FTSE 100 closed lower on Monday as a sharp sell-off in AstraZeneca weighed heavily on the index, overshadowing broader optimism across European markets. The FTSE 100 index ended the session down
More
Savvy investors are always searching for opportunities to get ahead of broader market movements before institutional money flows in. Identifying stocks before Wall Street analysts issue formal buy ratings can give retail
More
A landmark jump in U.S. factory activity is signalling the economy may be shaking off the weight of tariffs, but a troubling inflation picture is intensifying pressure on policymakers. The Institute for
More
The FTSE 100 slipped into negative territory as a sharp sell-off in AstraZeneca (AZN) shares weighed heavily on the index’s overall performance. AstraZeneca is one of the most heavily weighted stocks on
More